
Reset all filters
01 1Cozaar
02 10Cozaar/Hyzaar
03 4Xywav
Losartan, Losartan Potassium Hydrochlorothiazide
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 15
2019 Revenue in Millions : 0
Growth (%) : New Launch
Losartan, Losartan Potassium Hydrochlorothiazide
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 386
2019 Revenue in Millions : 442
Growth (%) : -13
Losartan, Losartan Potassium Hydrochlorothiazide
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 357
2020 Revenue in Millions : 386
Growth (%) : -8
Losartan, Losartan Potassium Hydrochlorothiazide
Main Therapeutic Indication : Sleep
Currency : USD
2021 Revenue in Millions : 535
2020 Revenue in Millions : 15
Growth (%) : 3,407
Losartan, Losartan Potassium Hydrochlorothiazide
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 323
2021 Revenue in Millions : 357
Growth (%) : -10
Losartan, Losartan Potassium Hydrochlorothiazide
Main Therapeutic Indication : Sleep
Currency : USD
2022 Revenue in Millions : 958
2021 Revenue in Millions : 535
Growth (%) : 79
Losartan, Losartan Potassium Hydrochlorothiazide
Main Therapeutic Indication : Sleep
Currency : USD
2023 Revenue in Millions : 1,273
2022 Revenue in Millions : 958
Growth (%) : 33
Losartan, Losartan Potassium Hydrochlorothiazide
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 281
2022 Revenue in Millions : 323
Growth (%) : -13
Losartan, Losartan Potassium Hydrochlorothiazide
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2024 Revenue in Millions : 243
2023 Revenue in Millions : 281
Growth (%) : -14
Main Therapeutic Indication : Antihypertensives
Currency : USD
2015 Revenue in Millions : 806
2014 Revenue in Millions : 667
Growth (%) : -17%